Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kazia Therapeutics Ltd (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KZIA
Nasdaq
8731
https://www.kaziatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kazia Therapeutics Ltd (ADR)
11 Best ASX Stocks To Buy Now
- Mar 24th, 2024 11:55 am
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
- Mar 21st, 2024 12:52 pm
Kazia announces presentation of new data at AACR Annual Meeting
- Mar 13th, 2024 12:00 pm
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
- Feb 21st, 2024 12:30 pm
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
- Jan 18th, 2024 12:30 pm
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
- Dec 5th, 2023 11:02 pm
Kazia Therapeutics Announces $2 Million Registered Direct Offering
- Dec 1st, 2023 1:00 pm
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
- Nov 29th, 2023 12:01 pm
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
- Nov 21st, 2023 12:30 pm
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
- Nov 20th, 2023 9:30 pm
Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week
- Nov 18th, 2023 12:40 pm
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
- Nov 15th, 2023 1:30 pm
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
- Nov 10th, 2023 12:01 pm
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
- Nov 1st, 2023 11:01 am
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
- Oct 23rd, 2023 11:01 am
Kazia announces voluntary delisting from ASX
- Oct 11th, 2023 11:01 am
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS
- Oct 5th, 2023 11:01 am
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
- Sep 29th, 2023 11:01 am
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
- Jul 6th, 2023 11:00 am
Insider Stock Buying Reaches AU$1.1m On Kazia Therapeutics
- Jul 4th, 2023 8:47 pm
Scroll